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Abstract
Hepatitis C is a fatal liver disease caused by the hepatitis C virus. In this study, blood donors, from various districts
of the KPK province and the federally administered tribal area (FATA) of Pakistan were tested for anti-HCV
antibodies and HCV RNA by ICT (Immuno-chromatographic test), ELISA and RT-PCR. Out of the 7148 blood donors,
224 (3.13%) were positive for anti-HCV antibodies by ICT, 135 (1.89%) by ELISA while 118 (1.65%) blood donors had
active HCV infection as detected by RT-PCR. We suggest that ELISA should be used for anti-HCV screening in
public sector hospitals and health care units.
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1. Background
Hepatitis C is caused by the hepatitis C virus (HCV),
which was identified in 1989 [1]. Hepatitis C virus has a
positive sense single-stranded RNA genome. The gen-
ome consists of a single open reading frame that is 9600
nucleotide bases long [2]. Contaminated blood, blood
products and body fluids are common modes of trans-
mission of HCV. Other risk factors include intravenous
drug abuse, use of barber razor, dental procedures, tat-
tooing, ear piercing, acupuncture and high-risk sexual
behavior [3]. About 3% of the world population is
infected with hepatitis-C virus [4]. Laboratory diagnosis
of HCV infection is usually made on the basis of the
detection of circulating antibodies. Serological tests for
detecting antibodies to HCV are generally classified as
screening tests or confirmatory tests. The most widely
used screening tests are ELISAs. Recently, other screen-
ing tests including agglutination, immunofilteration and
immunochromatographic tests have been developed [5].
Earlier studies have reported the prevalence of anti-
HCV antibodies among the blood donors or general
population from KPK province (Previously called N-W.
F.P) using Immunochromatographic tests [6-8] while
active infection has never been investigated. With the
p u r p o s eo fi n v e s t i g a t i n gt h ep r e v a l e n c eo fa c t i v eH C V
infection and analyzing the scope of antibody-based
HCV detection for screening blood and blood products,
we tested 7148 blood donors for anti-HCV or HCV
RNA by ICT, ELISA and Real-time PCR. Our results
indicated that the prevalence of anti-HCV antibodies as
detected by ELISA as well as the prevalence of active
HCV infection were lower as compared to the previous
studies which were based on antibody-based tests alone
while the prevalence of anti-HCV antibodies based on
Immunochromatographic tests fell in the range of pre-
viously documented prevalence rates in KPK.
2. Methods
The aim of this study was to analyze the prevalence of
the anti-HCV antibodies or HCV RNA among the blood
donors of KPK and the federally administered areas
(FATA) of Pakistan from January to September 2009.
T h r e ed i f f e r e n tm e t h o d sw e r eu s e dt of i n do u tt h ep r e -
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was also evaluated.
Blood donors
Blood samples was taken from the voluntary blood
donors and examined either at Hayat Abad Medical
Complex (HMC) or at the Institute of Biotechnology
and Genetic Engineering, KPK Agricultural University
Peshawar.
Immuno-chromatographic tests (ICT)
Initially all the blood donors were tested for anti-HCV
antibodies by immuno-chromatographic tests. Each
positive sample was tested twice. The immune-chroma-
tographic strips used in this study were from two differ-
ent sources. Samples positive by ICT technique were
further evaluated using ELISA.
ELISA
Sera positive by ICT were tested for anti-HCV antibo-
dies by ELISA (BIOKIT, S.A, Barcelona-Spain) according
to the manufacturer’s instructions. All the ELISA posi-
tive samples were processed for RNA extraction.
RNA Isolation and Real Time PCR
RNA isolation from the HCV positive ELISA samples
and subsequent RT-PCR was carried out with the help
of RNA extraction and RT-PCR kit from Sacace (Sacace,
Biotechnology, Italy) according to the manufacturer’s
instructions, inside the Cepheid smart cycler (Nasdaq:
CPHD, California, US).
3. Results
HCV prevalence among the blood donors in KPK and
FATA
A total of 7148 voluntary blood donors were initially
screened for anti HCV antibody by ICT. 3.13% of the
volunteers were detected positive for anti-HCV antibo-
dies (Table 1). All the samples positive by ICT were
further processed by ELISA which indicated that out of
the total number of volunteers, 1.89% were positive for
anti-HCV antibodies by ELISA (Table 1).
Samples positive by either ICT or ELISA were used
for HCV RNA extraction and subsequent RT-PCR. The
real-time PCR assay revealed that 118 (1.65%) donors
had HCV RNA in their blood (Table 1).
4. Discussion
Viral hepatitis is rapidly spreading among the general
population of Pakistan. The lack of proper screening
facilities or expertise in screening blood and blood pro-
ducts for possible HCV infection at our public sector
hospitals is partly contributing towards the spread of
HCV. Previous studies on HCV prevalence based on
anti-HCV antibodies among the blood donors have
revealed high prevalence rate in KPK province [6,8-10].
High prevalence of HCV among the blood donors has
also been reported from other parts of the country as
well [11-14]. Majority of the studies undertaken have
relied on the detection of antibodies against HCV and
active infection among the blood donors has never been
figured out. In our study, we have coupled the antibo-
dies-based tests with modern RT-PCR based HCV RNA
detection in order to exactly figure out the prevalence of
active HCV infection among the blood donors from
KPK and FATA region. Other studies from KPK men-
tioned earlier in this section have reported anti-HCV
prevalence from 3 to 4%. In this study, screening of
blood by ICT devices revealed that 3.13% of the blood
donors were positive for anti-HCV which is well in the
range of previously reported anti-HCV prevalence. As
false positivity is a common problem associated with
ICT devices [15-17] so in order to refine the screening
procedure we analyzed all the ICT positive samples by
3
rd generation ELISA which indicated that 1.89% of the
blood donors had antibodies against HCV. Seventeen
(12.6%) blood donors who were positive for anti-HCV
by ICT turned out to be negative by ELISA. These
results reveal that screening of blood and blood pro-
ducts by ICT devices may not predict the true picture
of anti-HCV prevalence. In KPK, screening of the blood
and blood products at maximum health care units is
carried out with ICT devices only. We suggest that
ELISA should replace ICT procedures for screening in
all health care units, especially those which are con-
cerned with immigration of the workers. Companies are
developing ELISAs for the detection of HCV core anti-
gen. These assays can be used in addition to anti-HCV
assays and may provide a valuable tool in the identifica-
tion of individuals undergoing HCV seroconversion.
T h e s ea s s a y sm a yb em o r ea p p r o p r i a t ea sas u p p l e m e n t
to anti-HCV antibody tests than using NAT for
Table 1 Prevalence of anti HCV and HCV RNA among the
blood donors of KPK and FATA region of Pakistan
MONTH DONORS Anti HCV
(ICT
+)
Anti HCV
(ELISA
+)
Real-time PCR
+
cases
JANUARY 974 34 21 20
FEBRUARY 1013 44 13 12
MARCH 972 23 15 14
APRIL 938 22 14 13
MAY 936 23 21 20
JUN 1095 25 18 18
JULY 673 23 12 11
AUGUST 547 30 11 10
8 7148 224 (3.13%) 135 (1.89%) 118 (1.65%)
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resources [5].
For confirmation of the active infection, we investi-
gated all the ELISA positive samples by Real-time PCR
which revealed that 1.65% of the blood donors had
HCV RNA in their blood. Presence of anti-HCV and
the absence of HCV RNA in the blood may be attribu-
ted to the self limiting nature of the disease in some
people or it may be due to the presence of antibodies
against HCV in treated subjects.
Conclusion
Prevalence of active HCV infection among the blood
donors of KPK province of Pakistan and the federally
administered tribal region of Pakistan is 1.65% which is
lower in comparison to the previous estimates. The
scope of ICT devices for screening against anti-HCV
seems to be limited. Proper and reliable HCV screening
should include latest ELISA procedures.
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